Status:

COMPLETED

UMCC 003 Cancer-Related Protein Biomarkers in Blood and Tumor Tissue of Patients With Cancer

Lead Sponsor:

University of Michigan Rogel Cancer Center

Collaborating Sponsors:

National Cancer Institute (NCI)

Conditions:

Breast Cancer

Colorectal Cancer

Eligibility:

All Genders

18+ years

Brief Summary

RATIONALE: Studying samples of blood and tumor tissue in the laboratory from patients with cancer and blood from healthy participants may help doctors learn more about changes that may occur in DNA an...

Detailed Description

OBJECTIVES: * Identify tumor antigens that induce a humoral response in patients with cancer. * Identify tumor-secreted proteins by special analysis in culture, and evaluate their expression patterns...

Eligibility Criteria

Inclusion

  • DISEASE CHARACTERISTICS:
  • Meets 1 of the following criteria (patient):
  • Scheduled to undergo primary surgical resection or first debulking surgery (prior to any anticancer treatment) for suspected or newly diagnosed cancer, including any of the following types:
  • Breast cancer
  • Adenocarcinoma of the colon
  • Adenocarcinoma or squamous cell carcinoma of the esophagus
  • Non-small cell lung cancer
  • Ovarian epithelial adenocarcinoma
  • Metastatic or unresectable cancer, including any of the following types:
  • Breast cancer
  • Adenocarcinoma of the colon
  • Adenocarcinoma or squamous cell carcinoma of the esophagus
  • Hepatoma
  • Non-small cell lung cancer
  • Small cell lung cancer
  • Ovarian epithelial adenocarcinoma
  • Adenocarcinoma of the pancreas
  • Meets the following criteria (healthy participant):
  • No chronic disease
  • Healthy participants with a history of cancer must be cancer-free for 5 years (skin cancer or carcinoma in situ of the cervix within the past 5 years allowed)
  • Willing to provide 60 mL of blood
  • Not a blood relative of an eligible and consenting cancer patient
  • PATIENT CHARACTERISTICS:
  • Able to tolerate the removal of 30-60 mL of blood
  • No feelings of light-headedness, dizziness, or fainting within the past 2 weeks
  • Pulse less than 100 on day of blood draw for study enrollment
  • PRIOR CONCURRENT THERAPY:
  • See Disease Characteristics
  • At least 3 weeks since prior chemotherapy or radiotherapy for metastatic or unresectable cancer
  • No concurrent chemotherapy
  • No concurrent radiotherapy

Exclusion

    Key Trial Info

    Start Date :

    June 1 2000

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    October 1 2007

    Estimated Enrollment :

    200 Patients enrolled

    Trial Details

    Trial ID

    NCT00900094

    Start Date

    June 1 2000

    End Date

    October 1 2007

    Last Update

    February 7 2012

    Active Locations (0)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 0 (0 locations)

    No Results Found

    We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.